PT - JOURNAL ARTICLE AU - Guillemette Thomas AU - Fleur Cohen Aubart AU - Laurent Chiche AU - Julien Haroche AU - Miguel Hié AU - Baptiste Hervier AU - Nathalie Costedoat-Chalumeau AU - Karine Mazodier AU - Mikael Ebbo AU - Philippe Cluzel AU - Nadège Cordel AU - David Ribes AU - Jean Chastre AU - Nicolas Schleinitz AU - Véronique Veit AU - Jean-Charles Piette AU - Jean-Robert Harlé AU - Alain Combes AU - Zahir Amoura TI - Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients AID - 10.3899/jrheum.160493 DP - 2017 Jan 01 TA - The Journal of Rheumatology PG - 24--32 VI - 44 IP - 1 4099 - http://www.jrheum.org/content/44/1/24.short 4100 - http://www.jrheum.org/content/44/1/24.full SO - J Rheumatol2017 Jan 01; 44 AB - Objective. Cardiac involvement during systemic lupus erythematosus (SLE) may include the pericardium, myocardium, valvular tissue, and coronary arteries. The aim of this study was to describe the clinical, biological, and radiological presentation of lupus myocarditis (LM) as well as the treatment response and longterm outcomes.Methods. We conducted a multicentric retrospective study of LM from January 2000 to May 2014.Results. Twenty-nine patients (3 men and 26 women) fulfilled the inclusion criteria (median age at the diagnosis of SLE: 30 yrs, range 16–57). Myocarditis was the first sign of SLE in 17/29 cases (58.6%). Troponin was elevated in 20/25 cases. Electrocardiogram results were abnormal in 25/28 cases. Echocardiography revealed low (≤ 45%) left ventricular ejection fraction (LVEF; 19/29, 66%) and pericardium effusion (20/29, 69%). Cardiac magnetic resonance imaging revealed delayed gadolinium enhancement in 9/13 patients (69%). Patients were treated with corticosteroids (n = 28), cyclophosphamide (CYC; n = 16), intravenous immunoglobulins (n = 8), and/or mycophenolate mofetil (n = 2). The median followup was 37 months. One month after the beginning of the treatment, 10/23 patients (43%) who had undergone echocardiography had an LVEF ≥ 55%. At the end of followup, 21/26 patients (81%) exhibited an LVEF ≥ 55%. Three patients died during followup, and 2 died from LM.Conclusion. LM is a severe manifestation of SLE. It can be the first manifestation of the disease or it can occur during followup, in particular in untreated patients. However, the longterm prognosis is typically positive. Patients with less severe disease exhibited good LVEF recovery without CYC.